Chief of the Division of Rheumatology
Northwell Health
Manhasset, New York, United States
Professional Title:
Chief, Division of Rheumatology, Northwell Health
Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell
Bio:
Dr. Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease. He also directs the Hospital’s SLE and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE. Regarded as one of the senior rheumatologists in the New York metropolitan area, he has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. For twenty years he served on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Dr. Furie’s favorite educational venue is at home with his colleagues and trainees.
Saturday, November 16, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose
Saturday, November 16, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose
MTP15A: Meet the Professor: Systemic Lupus Erythematosus
Sunday, November 17, 2024
11:30 AM – 12:30 PM Eastern Time
Disclosure(s): Alexion: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); BMS: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Genentech: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); iCell: Consultant (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Kyverna: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Remegen: Advisor or Review Panel Member (Ongoing)
MTP15B: Meet the Professor: Systemic Lupus Erythematosus
Sunday, November 17, 2024
4:30 PM – 5:30 PM Eastern Time
Disclosure(s): Alexion: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); BMS: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Genentech: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); iCell: Consultant (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Kyverna: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Remegen: Advisor or Review Panel Member (Ongoing)
Sunday, November 17, 2024
5:45 PM – 7:45 PM Eastern Time
No financial relationships with ineligible companies to disclose
Monday, November 18, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose